<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/517D56CB-2E67-4945-B0A5-37E7F81A865A"><gtr:id>517D56CB-2E67-4945-B0A5-37E7F81A865A</gtr:id><gtr:name>Takeda Cambridge Ltd</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/ADA1B507-CBF8-4F62-9B5C-9D2E9D2D700D"><gtr:id>ADA1B507-CBF8-4F62-9B5C-9D2E9D2D700D</gtr:id><gtr:name>European Union</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/620DB27D-4014-4278-AAD1-11105CC6BDEA"><gtr:id>620DB27D-4014-4278-AAD1-11105CC6BDEA</gtr:id><gtr:name>Novo Nordisk</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/4A348A76-B2D0-4DDD-804A-CE735A6D3798"><gtr:id>4A348A76-B2D0-4DDD-804A-CE735A6D3798</gtr:id><gtr:name>University of Bristol</gtr:name><gtr:department>Sch of Medical Sciences</gtr:department><gtr:address><gtr:line1>Senate House</gtr:line1><gtr:line4>Bristol</gtr:line4><gtr:line5>Avon</gtr:line5><gtr:postCode>BS8 1TH</gtr:postCode><gtr:region>South West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/4A348A76-B2D0-4DDD-804A-CE735A6D3798"><gtr:id>4A348A76-B2D0-4DDD-804A-CE735A6D3798</gtr:id><gtr:name>University of Bristol</gtr:name><gtr:address><gtr:line1>Senate House</gtr:line1><gtr:line4>Bristol</gtr:line4><gtr:line5>Avon</gtr:line5><gtr:postCode>BS8 1TH</gtr:postCode><gtr:region>South West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/517D56CB-2E67-4945-B0A5-37E7F81A865A"><gtr:id>517D56CB-2E67-4945-B0A5-37E7F81A865A</gtr:id><gtr:name>Takeda Cambridge Ltd</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/ADA1B507-CBF8-4F62-9B5C-9D2E9D2D700D"><gtr:id>ADA1B507-CBF8-4F62-9B5C-9D2E9D2D700D</gtr:id><gtr:name>European Union</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/620DB27D-4014-4278-AAD1-11105CC6BDEA"><gtr:id>620DB27D-4014-4278-AAD1-11105CC6BDEA</gtr:id><gtr:name>Novo Nordisk</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/B6F6A78A-A586-4C1D-A512-5169ACE7BB6D"><gtr:id>B6F6A78A-A586-4C1D-A512-5169ACE7BB6D</gtr:id><gtr:firstName>Richard</gtr:firstName><gtr:otherNames>John</gtr:otherNames><gtr:surname>Coward</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=MR%2FK010492%2F1"><gtr:id>925F27F9-18E7-45D0-AA68-AF2A77CAE6C8</gtr:id><gtr:title>Insulin signalling to the podocyte; pathological importance and therapeutic potential.</gtr:title><gtr:status>Active</gtr:status><gtr:grantCategory>Fellowship</gtr:grantCategory><gtr:grantReference>MR/K010492/1</gtr:grantReference><gtr:abstractText>The number of people in the world who are developing end stage kidney failure is rapidly increasing principally due to this condition being associated with diabetes. When this occurs patients require multiple medications, together with dialysis or kidney transplantation, or they die. Discovering new ways to prevent kidney failure is therefore critical. We have discovered that a cell, called the podocyte, in the kidney is implicated in the early stages of kidney disease (before the kidney completely fails) and this cell is responsive to a hormone called insulin. It appears that this cell needs insulin to remain healthy. We now want to understand exactly how insulin signals to the podocyte and explore if increasing insulin sensitivity of the this cell can prevent the kidney from completely failing. If this is true then strategies that increase podocyte insulin sensitivity could have great therapeutic potential in preventing kidney failure and stopping patients needing dialysis or kidney transplantation.</gtr:abstractText><gtr:technicalSummary>The loss of albumin into the urine is called albuminuria and this, if prolonged, results in kidney failure and cardiovascular disease. A key cell in the filtration barrier of the kidney that prevents albuminuria is called the podocyte. We have recently shown that the podocyte is an insulin responsive cell type and that when insulin sensitivity of this cell is lost it results in widespread renal damage. In the pathogenesis of diabetic nephropathy, and indeed all forms of chronic kidney disease (CKD), there is associated cellular insulin resistance which starts early in the process. Diabetic nephropathy is the leading cause of kidney failure in the world.

The aims of this project are to: 

(1) Focus on the proximal insulin signalling apparatus in the podocyte to understand the biological roles of the two major receptors through which insulin can signal, the insulin and the IGF-1 receptor, and map the signalling pathways they elicit. The importance of these receptors will be assessed in development and maturity. We will then go on to map the molecular pathways in the glomerulus which these receptors are modulating to understand the mechanisms underlying renal damage that occur when their signalling capabilities are diminished.

(2) Examine if enhancing insulin sensitivity specifically in the podocyte protects against the development of renal failure associated with diabetes mellitus. If true, this has great therapeutic potential.</gtr:technicalSummary><gtr:potentialImpactText>Realising the objective of this programme of research will benefit the following groups:

1. Patients with glomerular disease - The main non-academic beneficiaries will be patients with kidney disease, which is an ever-growing scourge in the developed world with major health economic implications. Improved understanding of the causes of proteinuria will lead to the development of new therapeutic targets combating both kidney failure and also associated cardiovascular disease. The likely timescale for this is 10-15 years. 

2. The general public. The other non-academic beneficiaries will be the public: I am committed to public engagement and have many years of experiencing of addressing lay groups including patients, carers and the general public. Improved education about the importance of urine testing for protein and screening for hypertension, diabetes and cardiovascular disease will have tangible health benefits in a relatively short timescale, within 1-2 years. I also regularly address medical professionals in East Africa where there is a huge burden of chronic renal disease. Identifying early preventative therapies for these patients is crucial as there is currently very limited provision for dialysis or transplantation here and the majority of patients who proceed into end stage renal failure die.

3. Charities - This research programme will make conceptual changes in several areas of glomerular biology and disease and so influence the direction of future research into avenues following the targets identified. This will allow more efficient use of scarce financial resources spent by charities on research.

4. Clinicians - understanding and developing treatments for patients with kidney diseases, both by identifying targets and subsequent design of clinical trials, will allow clinicians to participate in the scientific advances being made as well as informing patients of new treatment options on the horizon.

5. Academic community- see previous section.

6. Industry - by forming additional partnerships with industrial/pharmaceutical companies we will develop new drug/compound pipelines based on targets that we identify in this programme, thus creating commercial opportunities for a worldwide market.

7. The UK economy. The UK currently has over 40,000 patients on renal replacement therapies, around 700 per million population, total cost over &amp;pound;700 million per year, over 2% of NHS budget being spent on 0.1% of the population. Recent UK government figures show that CKD affects at least 3% of the population. This programme of work will directly address the commonest causes of permanent renal failure including Diabetic nephropathy (DN).
- Among patients starting renal replacement therapy, the incidence of DN doubled from the years 1991-2001
- DN accounts for 30-40% of patients with ESRD, with the incidence increasing year on year, mirroring the current worldwide rise in obesity and type II diabetes.
Through the mechanisms we propose, a target decrease in progression of diseases to ESRD of 30% would save &amp;pound;84M per year, and of just 10% would save &amp;pound;28M per year for the NHS.</gtr:potentialImpactText><gtr:fund><gtr:end>2019-07-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2013-07-31</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>1463941</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Takeda Cambridge Ltd</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Takeda industry academic collaboration</gtr:description><gtr:id>E25A2475-2A88-4C1E-AA8E-640F56C4863A</gtr:id><gtr:impact>Only 6 months old.</gtr:impact><gtr:outcomeId>56dc7e05d314c6.16528207-1</gtr:outcomeId><gtr:partnerContribution>This is a collaborative project with intellectual input from both parties.</gtr:partnerContribution><gtr:piContribution>This is a post-doctoral 2 year project funded by Takeda to study podocyte biology in insulin resistance in relation to ER stress.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2016-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Novo Nordisk</gtr:collaboratingOrganisation><gtr:country>Denmark, Kingdom of</gtr:country><gtr:description>Post-doctoral Research Fellow sponsored by industry</gtr:description><gtr:id>3CBB3EEA-615B-422C-97B9-E222BCA6E47E</gtr:id><gtr:impact>Only began 2 months ago</gtr:impact><gtr:outcomeId>54624b5b2d8ac0.61410195-1</gtr:outcomeId><gtr:partnerContribution>Financial support and intellectual input</gtr:partnerContribution><gtr:piContribution>Intellectual input in this collaborative project.</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>European Union</gtr:collaboratingOrganisation><gtr:country>European Union (EU)</gtr:country><gtr:description>Co lead of work package for IMI European Union project</gtr:description><gtr:id>D1110294-8488-440D-8431-C476C0C27179</gtr:id><gtr:impact>Just started!</gtr:impact><gtr:outcomeId>58c879b599dac6.56197559-1</gtr:outcomeId><gtr:partnerContribution>Multiple industrial partners are involved in this project.</gtr:partnerContribution><gtr:piContribution>We are part of a major European Union directive to study diabetic kidney disease. I am co lead for the Experimental medicine arm of this project.</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2017-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>University Press release and local media interest in Collaborative European grant investigating diabetic kidney disease</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>7C908D34-863B-4322-8AF7-054DD8CF19F1</gtr:id><gtr:impact>The university produced a Press release about the recent Collaborative European grant investigating biomarkers associated with diabetic kidney disease.</gtr:impact><gtr:outcomeId>58c83213a55187.89739807</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Media (as a channel to the public)</gtr:primaryAudience><gtr:url>http://www.bristol.ac.uk/news/2017/february/beat-dkd.html</gtr:url><gtr:year>2017</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Asked to speak on Radio 5 live about kidney stones</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>4E12330A-A92F-4B11-B238-E422AE6D1D4F</gtr:id><gtr:impact>Highlighting that kidney disease and kidney stones are an issue for the general public and that more research needs to be performed to understand them in more detail.</gtr:impact><gtr:outcomeId>58c8308956f0e3.16603520</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Media (as a channel to the public)</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>5000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Medical Student Research bursary- Identifying key insulin signalling pathways in the podocyte</gtr:description><gtr:end>2017-05-02</gtr:end><gtr:fundingOrg>Kidney Research UK</gtr:fundingOrg><gtr:id>AE24407B-8B80-4542-AA37-0E270F5A03A6</gtr:id><gtr:outcomeId>58c8285a73e5d8.32536610</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2016-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>220000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Takeda scientific industry grant</gtr:description><gtr:end>2017-08-02</gtr:end><gtr:fundingOrg>Takeda Cambridge Ltd</gtr:fundingOrg><gtr:id>5FDEDBAC-D24D-4FE6-8309-9F485FE73C50</gtr:id><gtr:outcomeId>56c387d31d1327.67645059</gtr:outcomeId><gtr:sector>Private</gtr:sector><gtr:start>2015-08-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>196588</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>KRUK project grant</gtr:description><gtr:end>2015-09-02</gtr:end><gtr:fundingOrg>Kidney Research UK</gtr:fundingOrg><gtr:id>1EA2FB70-8D03-4B22-885C-B0ED526B1531</gtr:id><gtr:outcomeId>HEkfCY3jT1m</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2012-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>31988</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>Wellcome Trust Institutional Strategic Support Fund</gtr:department><gtr:description>Clinical Primer</gtr:description><gtr:end>2015-07-02</gtr:end><gtr:fundingOrg>Wellcome Trust</gtr:fundingOrg><gtr:id>C5EC5EA7-4BC6-41F0-9883-4A922192F076</gtr:id><gtr:outcomeId>5462838de73546.94510564</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2014-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>221000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Clinical PhD Studentship examining Shiga toxin HUS</gtr:description><gtr:end>2019-10-02</gtr:end><gtr:fundingOrg>Kidney Research UK</gtr:fundingOrg><gtr:id>9A87E88F-DA62-4B0E-B37C-983C1BEFF84B</gtr:id><gtr:outcomeId>58c82a34cd2e60.56842469</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2016-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>209000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>Wellcome Trust Bloomsbury Centre</gtr:department><gtr:description>&amp;quot;MicroRNA regulation of insulin signalling in the podocyte&amp;quot; Clinical PhD project</gtr:description><gtr:end>2019-10-02</gtr:end><gtr:fundingOrg>Wellcome Trust</gtr:fundingOrg><gtr:id>7381434E-2E72-4251-82C6-107342F64D75</gtr:id><gtr:outcomeId>58c82aff3fc0e0.95330088</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2016-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>500000</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>EUR</gtr:currCode><gtr:currCountryCode>Austria</gtr:currCountryCode><gtr:currLang>de_AT</gtr:currLang><gtr:department>Innovative Medicines Initiative (IMI)</gtr:department><gtr:description>European Union IMI grant &amp;quot;BEAt DKD&amp;quot;</gtr:description><gtr:end>2021-08-02</gtr:end><gtr:fundingOrg>European Commission</gtr:fundingOrg><gtr:id>60B224A6-D81C-4258-9582-9375863968C7</gtr:id><gtr:outcomeId>58c8295b51ce08.55368697</gtr:outcomeId><gtr:sector>Multiple</gtr:sector><gtr:start>2017-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>5000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>KRUK Medical Student Fellowship- Developing a human cystinuria proximal tubular cell model</gtr:description><gtr:end>2017-06-02</gtr:end><gtr:fundingOrg>Kidney Research UK</gtr:fundingOrg><gtr:id>5F240509-316B-49FB-AA5C-6251CBFD551C</gtr:id><gtr:outcomeId>58c827a160d324.74672110</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2016-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>186000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>&amp;quot;Investigating adeno- associated virus as a vector for gene therapy in steroid resistant nephrotic syndrome&amp;quot; Kidney Research UK Clinical Fellowship</gtr:description><gtr:end>2019-01-02</gtr:end><gtr:fundingOrg>Kidney Research UK</gtr:fundingOrg><gtr:id>5649948A-68F6-4AD2-85C5-64865C95E86D</gtr:id><gtr:outcomeId>58c82c3f4b0ae2.51863825</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2016-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>234000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>&amp;quot;Aldosterone-induced endothelial glycocalyx dysfunction, a potential therapeutic target in proteinuria?&amp;quot; MRC clinical PhD Fellowship</gtr:description><gtr:end>2018-10-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>5C7CCA69-C469-4D87-A472-ED650D885AA9</gtr:id><gtr:outcomeId>58c82bb2b70296.68430560</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2015-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>66000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Developing a high throughput assay to study cystinuric kidney disease</gtr:description><gtr:end>2018-04-02</gtr:end><gtr:fundingOrg>Kidney Research UK</gtr:fundingOrg><gtr:id>E3FC9674-D18C-44F8-8303-B80375980C99</gtr:id><gtr:outcomeId>58c82e13a18477.20842984</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2017-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Medical student Inspire grant</gtr:description><gtr:end>2015-07-02</gtr:end><gtr:fundingOrg>Wellcome Trust</gtr:fundingOrg><gtr:id>4756446A-6B8E-4A11-90F3-011A636B7F24</gtr:id><gtr:outcomeId>56dc84b014ab00.76461661</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2015-06-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>156748</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Kidney Research UK project grant</gtr:description><gtr:end>2017-04-02</gtr:end><gtr:fundingOrg>Kidney Research UK</gtr:fundingOrg><gtr:id>6B8B7323-44F9-454F-ACFE-92A252219AF2</gtr:id><gtr:outcomeId>5462824a0a4cc6.60222024</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2014-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>36000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>&amp;quot;Using the fruit fly Drosophila to understand podocyte biology in diabetic nephropathy - a pilot study&amp;quot; Kidney Research UK innovation grant</gtr:description><gtr:end>2017-10-02</gtr:end><gtr:fundingOrg>Kidney Research UK</gtr:fundingOrg><gtr:id>D9E26BF3-EF75-43B1-8576-2F759AAC6181</gtr:id><gtr:outcomeId>58c82cd3d2ed05.33155358</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2016-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>200000</gtr:amountPounds><gtr:country>Denmark, Kingdom of</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Science-Industry grant</gtr:description><gtr:end>2016-04-02</gtr:end><gtr:fundingOrg>Novo Nordisk</gtr:fundingOrg><gtr:id>830D5F69-5694-4831-8C9A-00BC5C6634BE</gtr:id><gtr:outcomeId>56c3877f39dc70.25467091</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2014-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>168000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>KRUK clinical PhD Fellowship</gtr:description><gtr:end>2014-11-02</gtr:end><gtr:fundingOrg>Kidney Research UK</gtr:fundingOrg><gtr:id>D8F93071-3198-48E9-ADDE-F24D3041A8DD</gtr:id><gtr:outcomeId>Nphwtm3XURk</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2012-05-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>5000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Student KRUK MSc research bursary</gtr:description><gtr:end>2016-06-02</gtr:end><gtr:fundingOrg>Kidney Research UK</gtr:fundingOrg><gtr:id>471A80A6-9377-44A7-9E11-995B12C5DB6B</gtr:id><gtr:outcomeId>56dc852d11d0d6.17076940</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2015-10-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>FCE508FA-A20D-416D-AA5B-4D013B926572</gtr:id><gtr:title>The molecular biology of pelvi-ureteric junction obstruction.</gtr:title><gtr:parentPublicationTitle>Pediatric nephrology (Berlin, Germany)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ae6e61148d99ca4eee037293b1ccbd9e"><gtr:id>ae6e61148d99ca4eee037293b1ccbd9e</gtr:id><gtr:otherNames>Jackson L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0931-041X</gtr:issn><gtr:outcomeId>58c8263b5a2b85.52395282</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7AE51F71-C5AF-48CE-89AD-7272A940EC21</gtr:id><gtr:title>Paediatrics, insulin resistance and the kidney.</gtr:title><gtr:parentPublicationTitle>Pediatric nephrology (Berlin, Germany)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/14ee23518ba81f986d8814529301cb76"><gtr:id>14ee23518ba81f986d8814529301cb76</gtr:id><gtr:otherNames>Marlais M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0931-041X</gtr:issn><gtr:outcomeId>5462435fcc87c1.93865236</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>37B08FC2-116B-469D-938B-C2C5BF08AA64</gtr:id><gtr:title>Recent advances in our understanding of insulin signalling to the podocyte.</gtr:title><gtr:parentPublicationTitle>Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2cacc184945ab7dc0064d31846befad1"><gtr:id>2cacc184945ab7dc0064d31846befad1</gtr:id><gtr:otherNames>Lay A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0931-0509</gtr:issn><gtr:outcomeId>pm_15036_26_24286976</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>98DC7E0B-FCD5-4593-99F3-2454BBA7E3E2</gtr:id><gtr:title>Podocytes, signaling pathways, and vascular factors in diabetic kidney disease.</gtr:title><gtr:parentPublicationTitle>Advances in chronic kidney disease</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5d585453474182b344712153e2911226"><gtr:id>5d585453474182b344712153e2911226</gtr:id><gtr:otherNames>Brosius FC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1548-5595</gtr:issn><gtr:outcomeId>pm_540e197e197164acf</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>646BEDAD-75C1-4164-866E-02066EE3A056</gtr:id><gtr:title>Insulin signaling: implications for podocyte biology in diabetic kidney disease.</gtr:title><gtr:parentPublicationTitle>Current opinion in nephrology and hypertension</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/692468434adff8373bad0ae1d698197d"><gtr:id>692468434adff8373bad0ae1d698197d</gtr:id><gtr:otherNames>Coward R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1062-4821</gtr:issn><gtr:outcomeId>doi_55f98698678753c6</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D54AA916-7BCD-40D5-BB6D-76E11544120B</gtr:id><gtr:title>Diabetic Nephropathy: Perspective on Novel Molecular Mechanisms.</gtr:title><gtr:parentPublicationTitle>Trends in endocrinology and metabolism: TEM</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/397951267c5917353ff0577501f2a63d"><gtr:id>397951267c5917353ff0577501f2a63d</gtr:id><gtr:otherNames>Gnudi L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1043-2760</gtr:issn><gtr:outcomeId>58c6fec2d70a95.10842827</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D1C6096F-14A0-463F-9014-E5810402BFCC</gtr:id><gtr:title>IRS2 and PTEN are key molecules in controlling insulin sensitivity in podocytes.</gtr:title><gtr:parentPublicationTitle>Biochimica et biophysica acta</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1d5f973476a68eda75db26b77f97fd34"><gtr:id>1d5f973476a68eda75db26b77f97fd34</gtr:id><gtr:otherNames>Santamaria B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0006-3002</gtr:issn><gtr:outcomeId>56c3848b37c654.93810782</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7CC018C3-40C0-49F5-BF14-B0FDFE899755</gtr:id><gtr:title>Matrix metalloproteinase 9-mediated shedding of syndecan 4 in response to tumor necrosis factor a: a contributor to endothelial cell glycocalyx dysfunction.</gtr:title><gtr:parentPublicationTitle>FASEB journal : official publication of the Federation of American Societies for Experimental Biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/63fa7cda348dcc283fa7925a31bbbfc1"><gtr:id>63fa7cda348dcc283fa7925a31bbbfc1</gtr:id><gtr:otherNames>Ramnath R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0892-6638</gtr:issn><gtr:outcomeId>5462438d173f36.76773958</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>759ADC80-D4DD-479A-AA16-F4F51C54FE72</gtr:id><gtr:title>Loss of the insulin receptor in murine megakaryocytes/platelets causes thrombocytosis and alterations in IGF signalling.</gtr:title><gtr:parentPublicationTitle>Cardiovascular research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/671c568b6807cd2047594a3b962ec3ab"><gtr:id>671c568b6807cd2047594a3b962ec3ab</gtr:id><gtr:otherNames>Moore SF</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0008-6363</gtr:issn><gtr:outcomeId>56c384c64f2f28.08767294</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1EF5FB8E-F3D8-4830-BC9D-41E5E97D4051</gtr:id><gtr:title>Clinical and genetic analysis of patients with cystinuria in the United Kingdom.</gtr:title><gtr:parentPublicationTitle>Clinical journal of the American Society of Nephrology : CJASN</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4e030039ab8ef99241323d604abfa64e"><gtr:id>4e030039ab8ef99241323d604abfa64e</gtr:id><gtr:otherNames>Rhodes HL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1555-9041</gtr:issn><gtr:outcomeId>5675e44162c42</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>685F2EBA-EAB2-4D1D-8DD0-B4022EF27C8B</gtr:id><gtr:title>Peroxisome proliferator activating receptor-? and the podocyte.</gtr:title><gtr:parentPublicationTitle>Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/edf666954d0c304ecb7dee3c58f4dcaa"><gtr:id>edf666954d0c304ecb7dee3c58f4dcaa</gtr:id><gtr:otherNames>Platt C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0931-0509</gtr:issn><gtr:outcomeId>58c6fec3171004.67273406</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3CB6E6ED-F658-4248-94F8-43FEA89062A1</gtr:id><gtr:title>Insulin directly stimulates VEGF-A production in the glomerular podocyte.</gtr:title><gtr:parentPublicationTitle>American journal of physiology. Renal physiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0507b86744af3f2696af41536021b2e6"><gtr:id>0507b86744af3f2696af41536021b2e6</gtr:id><gtr:otherNames>Hale LJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1522-1466</gtr:issn><gtr:outcomeId>doi_15036_00548_2012</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>566DF79C-8F6D-437E-9898-53EDF48D59EA</gtr:id><gtr:title>VEGF regulates local inhibitory complement proteins in the eye and kidney.</gtr:title><gtr:parentPublicationTitle>The Journal of clinical investigation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a1c1ce1e3361cf7210c0858e347d1ea2"><gtr:id>a1c1ce1e3361cf7210c0858e347d1ea2</gtr:id><gtr:otherNames>Keir LS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0021-9738</gtr:issn><gtr:outcomeId>58c6fec2a72fb6.39551792</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F5615EFB-6A79-4B9C-8645-8861A6AFC076</gtr:id><gtr:title>Advances in our understanding of the pathogenesis of hemolytic uremic syndromes.</gtr:title><gtr:parentPublicationTitle>American journal of physiology. Renal physiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d222e9a41857fdee50700ee7e949463c"><gtr:id>d222e9a41857fdee50700ee7e949463c</gtr:id><gtr:otherNames>Bowen EE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>1522-1466</gtr:issn><gtr:outcomeId>5aa7cc9e9f5cc7.23235736</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A89023F1-B313-436C-B335-8DBC881EB09D</gtr:id><gtr:title>Enhanced insulin receptor, but not PI3K, signalling protects podocytes from ER stress.</gtr:title><gtr:parentPublicationTitle>Scientific reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/30f284c1b088b835ae91a600e1579bb6"><gtr:id>30f284c1b088b835ae91a600e1579bb6</gtr:id><gtr:otherNames>Garner KL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>2045-2322</gtr:issn><gtr:outcomeId>5aa7cc61186670.08380284</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D2C6BF11-BA4C-484A-AFC4-409E0F44E239</gtr:id><gtr:title>Initial steroid sensitivity in children with steroid-resistant nephrotic syndrome predicts post-transplant recurrence.</gtr:title><gtr:parentPublicationTitle>Journal of the American Society of Nephrology : JASN</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a1d5e9e98b6d1b5c61f6e79481794254"><gtr:id>a1d5e9e98b6d1b5c61f6e79481794254</gtr:id><gtr:otherNames>Ding WY</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1046-6673</gtr:issn><gtr:outcomeId>pm_15036_26_24511128</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>96B39A31-DE3F-4B8F-A843-B5FC33495821</gtr:id><gtr:title>DBA2J db/db mice are susceptible to early albuminuria and glomerulosclerosis that correlate with systemic insulin resistance.</gtr:title><gtr:parentPublicationTitle>American journal of physiology. Renal physiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/214d5b30e8f132e30229825d2c81a0dc"><gtr:id>214d5b30e8f132e30229825d2c81a0dc</gtr:id><gtr:otherNames>?stergaard MV</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1522-1466</gtr:issn><gtr:outcomeId>58c6fec25a15f3.38647065</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B7C80A05-58D5-4D35-B737-39C22AA0734F</gtr:id><gtr:title>Genetics and the nephron.</gtr:title><gtr:parentPublicationTitle>Archives of disease in childhood. Education and practice edition</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/14ee23518ba81f986d8814529301cb76"><gtr:id>14ee23518ba81f986d8814529301cb76</gtr:id><gtr:otherNames>Marlais M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1743-0585</gtr:issn><gtr:outcomeId>pm_15036_26_24163356</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>24EB3148-0CEC-4B3B-9714-3D81E62B80B1</gtr:id><gtr:title>Prolonged exposure of mouse and human podocytes to insulin induces insulin resistance through lysosomal and proteasomal degradation of the insulin receptor.</gtr:title><gtr:parentPublicationTitle>Diabetologia</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ab0c1bdc33924560c58f52d919227b6f"><gtr:id>ab0c1bdc33924560c58f52d919227b6f</gtr:id><gtr:otherNames>Lay AC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0012-186X</gtr:issn><gtr:outcomeId>5a2fb07396aee2.74349168</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">MR/K010492/1</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>160D22D0-5677-4513-A0AC-7F3526B7F336</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>Metabolic and Endocrine</gtr:text></gtr:healthCategory><gtr:healthCategory><gtr:id>2EEE0958-6BE1-4D16-B86B-5D954CD37219</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>Renal and Urogenital</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>CF950C9A-DB16-4E23-8AEB-94548777BCA1</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>1.1  Normal biological development and functioning</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>